IRIS
BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.509
EU - Europa 598
AS - Asia 114
AF - Africa 2
Totale 2.223
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.507
IE - Irlanda 268
SE - Svezia 161
IT - Italia 98
SG - Singapore 98
GB - Regno Unito 56
IN - India 11
AT - Austria 4
FI - Finlandia 4
DE - Germania 3
BE - Belgio 2
CA - Canada 2
NG - Nigeria 2
UA - Ucraina 2
VN - Vietnam 2
CN - Cina 1
JP - Giappone 1
MY - Malesia 1
Totale 2.223
Salva come PNG Salva come JPEG
Città #
Chandler 297
Dublin 268
Ashburn 226
Fairfield 123
Lawrence 104
Princeton 104
San Diego 59
Washington 52
Des Moines 49
New York 48
Boardman 40
Seattle 28
London 26
Turin 24
Redmond 21
Pune 11
Ancona 9
Cambridge 9
Woodbridge 9
Houston 8
Los Angeles 6
Marche 5
Bologna 4
Boydton 4
Hounslow 4
Macerata 4
Southwark 4
Vienna 4
Chiswick 3
Helsinki 3
Islington 3
Kilburn 3
Prescot 3
Rome 3
Wandsworth 3
Ann Arbor 2
Brussels 2
Dueville 2
Genoa 2
Hanoi 2
Ikeja 2
Mountain View 2
New Bedfont 2
Sassari 2
Tolentino 2
Toronto 2
Wilmington 2
Campobasso 1
Centro 1
Changsha 1
Chicago 1
Falconara Marittima 1
Falkenstein 1
Falls Church 1
Laurel 1
Miami Beach 1
Mondolfo 1
Nashville 1
Newark 1
Palermo 1
Pedaso 1
Petaling Jaya 1
Ravenna 1
Suzuka 1
Totale 1.612
Salva come PNG Salva come JPEG
Nome #
The application of cancer stem cell model in malignant mesothelioma 66
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 50
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 49
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 47
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 44
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 41
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 39
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 37
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 35
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 34
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 34
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 32
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 31
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 31
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 31
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 31
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 30
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 29
Germline copy number variation in the YTHDC2 gene: Does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 29
Sorafenib for the treatment of breast cancer 29
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 28
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 28
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 28
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 28
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 27
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 27
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 27
Bortezomib: A new pro-apoptotic agent in cancer treatment 27
New generation anaplastic lymphoma kinase inhibitors 27
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 27
The role of targeted therapy for gastrointestinal tumors 27
Cancer and the microbiome: Potential applications as new tumor biomarker 26
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 26
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 26
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 26
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 25
VIPoma and PPoma 25
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 25
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 25
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 25
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 25
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 25
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 25
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 24
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 24
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 24
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 24
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 23
How much of familial breast cancer risk is currently explained by the known genes? 23
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 22
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 22
EGFR genomic alterations in cancer: prognostic and predictive values 22
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 22
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 22
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 22
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 21
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 21
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 21
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 21
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 20
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 20
A headlight on liquid biopsies: a challenging tool for breast cancer management 20
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 19
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 19
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 18
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 18
MicroRNAs in colorectal cancer stem cells: New regulators of cancer stemness? 18
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 18
Anti-endothelin drugs in solid tumors 17
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 16
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 16
Nintedanib in NSCLC: Evidence to date and place in therapy 16
Colorectal cancer 16
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 15
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 15
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 15
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 15
Fully human antibodies for malignant pleural mesothelioma targeting 15
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 15
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 14
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 14
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 14
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 14
HER2-positive male breast cancer: An update 13
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 13
Targeted therapies in hepatocellular carcinoma 13
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 13
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 13
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 12
Tmb in nsclc: A broken dream? 12
Dietary restriction: could it be considered as speed bump on tumor progression road? 12
Multisciplinary management of patients with liver metastasis from colorectal cancer 12
Sex steroids, carcinogenesis, and cancer progression 12
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 11
Ramucirumab and its use in gastric cancer treatment 11
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 11
Monoclonal antibodies in gastrointestinal cancers 11
Well-being among Italian medical oncologists: An exploratory study 11
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 11
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 11
Totale 2.311
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.973
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022515 0 0 0 0 0 0 0 0 237 13 153 112
2022/20231.116 106 67 91 59 78 196 2 55 343 5 81 33
2023/2024783 157 17 79 122 158 185 25 30 0 10 0 0
Totale 2.414